RT Journal Article
SR Electronic
T1 Staphylococcal superantigens promote bacterial persistence following postoperative surgical site infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.23.24310826
DO 10.1101/2024.07.23.24310826
A1 Dufresne, Karine
A1 Tuffs, Stephen W.
A1 Walton, Nicholas R.
A1 Kasper, Katherine J.
A1 Mohorovic, Ivor
A1 Hasan, Farah
A1 Bentall, Tracey
A1 Heinrichs, David E.
A1 Delport, Johan
A1 Mele, Tina S.
A1 McCormick, John K.
YR 2024
UL http://medrxiv.org/content/early/2024/07/24/2024.07.23.24310826.abstract
AB Staphylococcus aureus is a predominant cause of postoperative surgical site infections and persistent bacteremia. Here we describe a patient that following a total knee arthroplasty subsequently experienced three episodes of S. aureus bacteremia over a period of 4 months. The initial blood stream isolate (SAB-0429) was a clonal complex (CC) 5 and methicillin resistant S. aureus (MRSA), whereas two subsequent blood stream isolates (SAB-0485 and SAB-0495) were CC5 isolates but methicillin sensitive S. aureus (MSSA). The two latter isolates harbored a plasmid encoding three superantigen genes not present in the primary MRSA isolate. SAB-0485 and SAB-0495 expressed the plasmid encoded staphylococcal enterotoxin R (SER) exotoxin and demonstrated increased superantigen activity compared with SAB-0429. Compared to SAB-0429, the latter isolates also demonstrated an increased bacterial burden in a mouse bacteremia model that was dependent on increased IFNγ production. Curing of the plasmid from SAB-0485 reduced this virulence phenotype. These findings suggest that the superantigen exotoxins may provide a selective advantage in chronic postsurgical infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by an operating grant from the Canadian Institutes of Health Research (CIHR) (PJT-166050) to S.W.T, T. S. M. and J.K.M and D.E.H acknowledges funding from CIHR grant PJT-168842.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For isolates from bacteremia patients, the study was reviewed and approved by the University of Western Ontario Health Sciences Research Ethics Board (HSREB #105167). For healthy donor blood draw, the study was reviewed and approved by the University of Western Ontario Health Sciences Research Ethics Board (HSREB #110859).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.